Secukinumab (Cosentyx®) is a fully human monoclonal antibody that selectively targets
interleukin (IL)-17A, a proinflammatory cytokine involved in the pathogenesis of psoriatic …

In recent years, the use of interleukin (IL) 23 inhibitors in the treatment of psoriatic arthritis
(PsA) has been the subject of much research. By specifically binding to the p19 subunit of IL …

Management recommendations are helpful for clinicians and patients because they provide
guidelines for the use of medications [1]. In psoriatic arthritis (PsA), several recommendation …

In inflammatory rheumatic disorders, the immune system attacks and damages the
connective tissues and invariably internal organs. During the past decade, remarkable …

Background We aimed to describe the uptake of newer biologic or targeted synthetic
disease-modifying antirheumatic drugs (b/tsDMARDs) in psoriatic arthritis (PsA) in the …

Psoriatic arthritis (PsA) is a complex, multiform and chronic inflammatory disease
characterized by the association of psoriasis and arthritis with other musculoskeletal and …

Objective Real‐world studies assessing treatment response by psoriatic arthritis (PsA)
domains are limited. This study aimed to describe the patient characteristics, frequency and …

Transcriptome profiling approaches have been widely used to investigate the mechanisms
underlying psoriasis pathogenesis. Most researchers have measured changes in transcript …

Aims Secukinumab, the first interleukin 17A inhibitor, is widely used to treat immune
diseases, including plaque psoriasis, psoriatic arthritis and ankylosing spondylitis. Recently …

Objective: Clinical trials involve the collection of a wealth of data, comprising multiple
diverse measurements performed at baseline and follow-up visits over the course of a trial …